Coya Therapeutics
COYA· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +1.2% in FY2025
Arun Swaminathan is the CEO of Coya Therapeutics and was paid $2.1M in FY2025 (Dec), up 40%.
Pay$100 in the stock at the end of FY22 → $122
Executives4
See all- 1Arun SwaminathanChief Executive Officer, DirectorFY2025
- 2Howard BermanFormer Chief Executive Officer, Former Executive Chairman of the BoardFY2025
- 3Fred GrossmanPresident, Chief Medical OfficerFY2025
- 4David SnyderChief Financial Officer and Chief Operating OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allCoya Therapeutics paid its 4 named executives $6.4M in total in FY2025 (Dec). CEO Arun Swaminathan was paid $2.1M of that.
| Name | |||
|---|---|---|---|
| Arun SwaminathanChief Executive Officer, Director | |||
| Howard BermanFormer Chief Executive Officer, Former Executive Chairman of the Board | |||
| Fred GrossmanPresident, Chief Medical Officer | |||
| David SnyderChief Financial Officer and Chief Operating Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Coya Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Activity
Filings6
See all| Proxy statement | DEF 14A | May 13, 2026 | FY2025 |
| Annual report | 10-K | Mar 16, 2026 | FY2025 |
| Proxy statement | DEF 14A | May 16, 2025 | FY2024 |
| Annual report | 10-K | Mar 18, 2025 | FY2024 |
| Proxy statement | DEF 14A | Mar 28, 2024 | FY2023 |
| Annual report | 10-K | Mar 19, 2024 | FY2023 |
